Moderna Inc. Banner Image

Moderna Inc.

  • Ticker MRNA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Moderna Inc. Logo Image
  • 501-1000 Employees
  • Based in Cambridge, Massachusetts
Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,900 participants, prior to enrolling the Phase 3 study of mRNA-1273, have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technologyMore has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.
4.8 / 5.0 (261)

Moderna Inc. reports have an aggregate usefulness score of 4.8 based on 261 reviews.

Moderna Inc.

Most Recent Annual Report

Moderna Inc.
MOST RECENT 2022 Annual Report and Form 10K
Add Annual Report To Cart

Older/Archived Annual Reports

Moderna Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!